Johnson & Johnson (JNJ) 106.04 $JNJ
New Board Director, Clinical Trial Results, New Drug Designations and Marketing Authorizations - Analyst Notes on Johnson & Johnson, Merck, Novartis, GSK and Endo
PR Newswire - 1 hr 6 mins ago
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), Novartis AG (NYSE: NVS), GlaxoSmithKline plc (NYSE: GSK) and Endo International PLC (NASDAQ: ENDP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4619-100free.
Jim Cramer's 'Mad Money' Recap: Hunting for Bargains
at The Street - Wed Jul 09, 6:53PM CDT
All you need to do is look at the last quarter's winners, Cramer advises.
Is Pharmacyclics the Next Celgene?
Todd Campbell, The Motley Fool - Motley Fool - Wed Jul 09, 1:00PM CDT
Pharmacyclics has made a big move in the past two years as investors have become increasingly excited by the potential for Imbruvica, a drug being co-developed with Johnson & Johnson that won its first FDA approval last November. Imbruvica...
Midday Glance: Pharmaceuticals companies
AP - Wed Jul 09, 12:36PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Wed Jul 09, 12:36PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Celgene Drug Otezla Fails Trial, But Street Sanguine
at Investor's Business Daily - Wed Jul 09, 10:52AM CDT
Big-cap biotech Celgene (CELG) reported Wednesday that its drug Otezla failed a trial for an inflammatory spinal disease, but the stock rebounded from an early drop as analysts said the news wasn't a surprise. The phase three study looked at Otezla...
Early Glance: Medical Devices companies
AP - Wed Jul 09, 9:30AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Early Glance: Pharmaceuticals companies
AP - Wed Jul 09, 9:30AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Will Fastenal (FAST) Beat Earnings Estimate in Q2? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 8:00AM CDT
Fastenal Company (FAST) is set to report second-quarter fiscal 2014 results on Jul 11, before the market opens.
Global Electrophysiology Ablation Catheters Market 2014-2018
M2 - Wed Jul 09, 5:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zpds69/global) has announced the addition of the "Global Electrophysiology Ablation Catheters Market 2014-2018" report to their offering. Catheter ablation is a minimally invasive procedure used to remove or destroy faulty electrical pathways from sections of the heart that promote irregular cardiac rhythms (also known as cardiac arrhythmias). Cardiac arrhythmias can be of several types, including atrial fibrillation, atrial flutter, and supraventricular tachycardia. Key Regions: - Americas - EMEA - APAC Key Vendors: - Boston Scientific Corp. - Johnson & Johnson - Medtronic Inc. - St. Jude Medical Inc. Other Prominent Vendors: - Advanced Cardiac Therapeutics Inc. - AtriCure Inc. - BIOTRONIK SE & Co. KG - CardioFocus Inc. - Edwards Lifesciences Corp. - Imricor Medical Systems Inc. - MicroPort Scientific Corp. - PLC Medical Systems Inc. - VIMECON GmbH Key Market Drivers: - Growing Incidence of Cardiac Arrhythmias. - For a full, detailed list, view the report. Key Market Challenges: - Presence of Substitutes. - For a full, detailed list, view the report. Key Market Trends: - High Adoption of Irrigated-tip EP Ablation Catheters. - For a full, detailed list, view the report. Key Questions Answered in this Report: - What will the market size be in 2018 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Technology 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - Advanced Cardiac Therapeutics Inc. - AtriCure Inc. - BIOTRONIK SE & Co. KG - Boston Scientific Corp. - CardioFocus Inc. - Edwards Lifesciences Corp. - Imricor Medical Systems Inc. - Johnson & Johnson - Medtronic Inc. - MicroPort Scientific Corp. - PLC Medical Systems Inc. - St. Jude Medical Inc. - VIMECON GmbH For more information visit http://www.researchandmarkets.com/research/zpds69/global
Fortune 500 Companies Recruit Talent at CAREERS & the disABLED Magazine's Career Expo
PR Newswire - Tue Jul 08, 1:01PM CDT
Equal Opportunity Publications, Inc. (EOP), the leading publisher of diversity recruitment print and online magazines, announces registration is open for CAREERS & the disABLED Magazine's Career Expo, July 18 at the Wyndham New Yorker Hotel in New York City, from 10 a.m. to 3 p.m.
Is This Johnson & Johnson's Worst Nightmare?
George Budwell, The Motley Fool - Motley Fool - Tue Jul 08, 1:00PM CDT
Johnson & Johnson has been one of the top-performing Dow stocks of 2014, rising nearly 18% year to date. J&J's performance has been driven primarily by stellar top-line growth in its pharmaceutical division, where year-over-year sales...
Johnson & Johnson to Make $25M Milestone Payment to Genmab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 12:10PM CDT
The payment was triggered by progress in an ongoing phase III study on experimental cancer treatment, daratumumab.
Novartis' CTL109 Gets Breakthrough Therapy Designation from the FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 11:00AM CDT
Novartis (NVS) announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, CTL019.
Global Contraceptives Market 2014-2018 with Actavis, Bayer AG, J&J's, Janssen Pharma, Merck & Co., Pfizer, & Teva Pharmaceutical Leading the Way
M2 - Tue Jul 08, 10:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d964b9/global) has announced the addition of the "Global Contraceptives Market 2014-2018" report to their offering. The global contraceptives market is set to grow at a CAGR of 5.90 percent over the period 2013-2018. The Global Contraceptives market is driven by several factors, of which the growing prevalence of unplanned pregnancies is one of the major drivers. In order to control the 41 percent of unplanned pregnancies out of 208.2 million pregnancies globally, there has been an increase in the number of initiatives by governments and NGOs. Furthermore, the report states that one of the major challenges is the introduction of low-cost generic contraceptives. Recently, pharmaceutical companies have introduced new products into their portfolios or diversified their contraceptive drugs and devices. This trend has been primarily supported by several prominent deals or partnerships to develop or introduce new products with better efficacy and safety profiles. These strategic decisions will help companies to generate revenue and acquire a significant share of the Global Contraceptives market. Some of the major acquisitions in this space include Conceptus Inc. by Bayer, Warner Chilcott plc by Actavis, Uteron Pharma SA by Watson Pharmaceuticals Inc., and Barr Pharmaceuticals Inc. by Teva Pharmaceutical Industries. Some of the other prominent deals include Bayer and USAID partnering to make Microgynon, an oral contraceptive and Starpharma Holdings licensing agreement with Okamoto Industries Inc. for the VivaGel-coated condom. The global contraceptives market can be segmented broadly into two divisions: Drugs and Devices. This report covers the present scenario and the growth prospects of the Global Contraceptives market for the period 2013-2018. To calculate the market size, the report considers revenue generated from the sales of various products used for contraception which include: - Drugs (Oral Contraceptive Pills, Injectable Contraceptives, Topical Contraceptives) - Devices (Male & Female condoms, Diaphragms, IUDs, Vaginal Rings, Female Sponges and Subdermal Contraceptive Implants) Key Vendors: - Actavis plc - Bayer AG - Johnson & Johnson's Janssen Pharmaceuticals, Inc. - Merck & Co. - Pfizer, Inc. - Teva Pharmaceutical Industries, Ltd Other Prominent Vendors: - Adamis Pharmaceuticals Corp. - Agile Therapeutics, Inc. - ANI Pharmaceuticals, Inc. - Ansell Ltd. - Apothecus Pharmaceutical Corp. - Blairex Laboratories Inc. - Church & Dwight, Co. Inc. - Caldwell Consumer Health, LLC. - Ferring International Center S.A - Fuji Latex Co., Ltd. - HLL Lifecare Limited - Mayer Laboratories - Medicines 360 - Karex Berhad - Lipocine Inc. - Lupin Pharmaceuticals, Inc. - Mylan Laboratories Inc. - Okamoto Industries, Inc. - Pantarhei Bioscience B.V. - Paul Hartmann AG - Reckitt Benckiser Group Plc - The Female Health Company For more information visit http://www.researchandmarkets.com/research/d964b9/global
Cognitive Impairment Associated With Schizophrenia (CIAS) Clinical Trials Review, H1, 2014
M2 - Tue Jul 08, 10:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/85qd7j/cognitive) has announced the addition of the "Cognitive Impairment Associated With Schizophrenia (CIAS) Global Clinical Trials Review, H1, 2014" report to their offering. Cognitive Impairment Associated With Schizophrenia (CIAS) Global Clinical Trials Review, H1, 2014" provides data on the Cognitive Impairment Associated With Schizophrenia (CIAS) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cognitive Impairment Associated With Schizophrenia (CIAS). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cognitive Impairment Associated With Schizophrenia (CIAS). Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - Pfizer Inc. - Novartis AG - Merck & Co., Inc. - AbbVie Inc. - Takeda Pharmaceutical Company Limited - Saniona AB - Johnson & Johnson - GlaxoSmithKline plc - VA Greater Los Angeles Healthcare Center - Hamamatsu University School of Medicine - Bronx Veterans Medical Research Foundation - Mashhad University of Medical Sciences - St. Marianna University School of Medicine - Yale University - Indiana University - Central South University - University of Southern Denmark - Northwestern University For more information visit http://www.researchandmarkets.com/research/85qd7j/cognitive
United States Hernia Repair Market Outlook to 2020
M2 - Tue Jul 08, 10:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sd7758/united_states) has announced the addition of the "United States Hernia Repair Market Outlook to 2020" report to their offering. "United States Hernia Repair Market Outlook to 2020", provides key market data on the United States Hernia Repair market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments - Synthetic Meshes (Synthetic Flat Meshes and Synthetic 3D Meshes), Composite Meshes and Biological Meshes. The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Hernia Repair market wherever available. The data in the report is derived from dynamic market forecast models. The objective is to provide information that represents the most up-to-date data of the industry possible. Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis. Scope - Market size data for Hernia Repair market segments - Synthetic Meshes (Synthetic Flat Meshes and Synthetic 3D Meshes), Composite Meshes and Biological Meshes. - Annualized market revenues (USD million), volume (units) and average prices (in US dollars) data for each of the market segments. Data is provided from 2005 to 2013 and forecast to 2020. - 2013 company shares and distribution shares data for Hernia Repair market. - Global corporate-level profiles of key companies operating within the Hernia Repair market. Key players covered include: - C. R. Bard, Inc. - Johnson & Johnson - Covidien plc - B. Braun Melsungen AG For more information visit http://www.researchandmarkets.com/research/sd...ted_states
Kony Appoints Two Industry Luminaries to Complete Executive Team
Business Wire - Tue Jul 08, 10:00AM CDT
Kony, Inc., the leading enterprise mobility company, today announced the appointment of Blake P. Salle as president of field operations and Neeraj Nityanand as executive vice president of global services and support. Salle will focus on driving Kony's continued growth and global expansion, while Nityanand will ensure Kony delivers the highest level of value and service to its growing base of Fortune 2000 customers.
New Board Director, Clinical Trial Results, New Drug Designations and Marketing Authorizations - Analyst Notes on Johnson & Johnson, Merck, Novartis, GSK and Endo
PR Newswire - 1 hr 6 mins ago
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), Novartis AG (NYSE: NVS), GlaxoSmithKline plc (NYSE: GSK) and Endo International PLC (NASDAQ: ENDP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4619-100free.
Jim Cramer's 'Mad Money' Recap: Hunting for Bargains
at The Street - Wed Jul 09, 6:53PM CDT
All you need to do is look at the last quarter's winners, Cramer advises.
Is Pharmacyclics the Next Celgene?
Todd Campbell, The Motley Fool - Motley Fool - Wed Jul 09, 1:00PM CDT
Pharmacyclics has made a big move in the past two years as investors have become increasingly excited by the potential for Imbruvica, a drug being co-developed with Johnson & Johnson that won its first FDA approval last November. Imbruvica...
Midday Glance: Pharmaceuticals companies
AP - Wed Jul 09, 12:36PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Wed Jul 09, 12:36PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Celgene Drug Otezla Fails Trial, But Street Sanguine
at Investor's Business Daily - Wed Jul 09, 10:52AM CDT
Big-cap biotech Celgene (CELG) reported Wednesday that its drug Otezla failed a trial for an inflammatory spinal disease, but the stock rebounded from an early drop as analysts said the news wasn't a surprise. The phase three study looked at Otezla...
Early Glance: Medical Devices companies
AP - Wed Jul 09, 9:30AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Early Glance: Pharmaceuticals companies
AP - Wed Jul 09, 9:30AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Will Fastenal (FAST) Beat Earnings Estimate in Q2? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 8:00AM CDT
Fastenal Company (FAST) is set to report second-quarter fiscal 2014 results on Jul 11, before the market opens.
Global Electrophysiology Ablation Catheters Market 2014-2018
M2 - Wed Jul 09, 5:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zpds69/global) has announced the addition of the "Global Electrophysiology Ablation Catheters Market 2014-2018" report to their offering. Catheter ablation is a minimally invasive procedure used to remove or destroy faulty electrical pathways from sections of the heart that promote irregular cardiac rhythms (also known as cardiac arrhythmias). Cardiac arrhythmias can be of several types, including atrial fibrillation, atrial flutter, and supraventricular tachycardia. Key Regions: - Americas - EMEA - APAC Key Vendors: - Boston Scientific Corp. - Johnson & Johnson - Medtronic Inc. - St. Jude Medical Inc. Other Prominent Vendors: - Advanced Cardiac Therapeutics Inc. - AtriCure Inc. - BIOTRONIK SE & Co. KG - CardioFocus Inc. - Edwards Lifesciences Corp. - Imricor Medical Systems Inc. - MicroPort Scientific Corp. - PLC Medical Systems Inc. - VIMECON GmbH Key Market Drivers: - Growing Incidence of Cardiac Arrhythmias. - For a full, detailed list, view the report. Key Market Challenges: - Presence of Substitutes. - For a full, detailed list, view the report. Key Market Trends: - High Adoption of Irrigated-tip EP Ablation Catheters. - For a full, detailed list, view the report. Key Questions Answered in this Report: - What will the market size be in 2018 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Technology 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - Advanced Cardiac Therapeutics Inc. - AtriCure Inc. - BIOTRONIK SE & Co. KG - Boston Scientific Corp. - CardioFocus Inc. - Edwards Lifesciences Corp. - Imricor Medical Systems Inc. - Johnson & Johnson - Medtronic Inc. - MicroPort Scientific Corp. - PLC Medical Systems Inc. - St. Jude Medical Inc. - VIMECON GmbH For more information visit http://www.researchandmarkets.com/research/zpds69/global
Fortune 500 Companies Recruit Talent at CAREERS & the disABLED Magazine's Career Expo
PR Newswire - Tue Jul 08, 1:01PM CDT
Equal Opportunity Publications, Inc. (EOP), the leading publisher of diversity recruitment print and online magazines, announces registration is open for CAREERS & the disABLED Magazine's Career Expo, July 18 at the Wyndham New Yorker Hotel in New York City, from 10 a.m. to 3 p.m.
Is This Johnson & Johnson's Worst Nightmare?
George Budwell, The Motley Fool - Motley Fool - Tue Jul 08, 1:00PM CDT
Johnson & Johnson has been one of the top-performing Dow stocks of 2014, rising nearly 18% year to date. J&J's performance has been driven primarily by stellar top-line growth in its pharmaceutical division, where year-over-year sales...
Johnson & Johnson to Make $25M Milestone Payment to Genmab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 12:10PM CDT
The payment was triggered by progress in an ongoing phase III study on experimental cancer treatment, daratumumab.
Novartis' CTL109 Gets Breakthrough Therapy Designation from the FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 11:00AM CDT
Novartis (NVS) announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, CTL019.
Global Contraceptives Market 2014-2018 with Actavis, Bayer AG, J&J's, Janssen Pharma, Merck & Co., Pfizer, & Teva Pharmaceutical Leading the Way
M2 - Tue Jul 08, 10:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d964b9/global) has announced the addition of the "Global Contraceptives Market 2014-2018" report to their offering. The global contraceptives market is set to grow at a CAGR of 5.90 percent over the period 2013-2018. The Global Contraceptives market is driven by several factors, of which the growing prevalence of unplanned pregnancies is one of the major drivers. In order to control the 41 percent of unplanned pregnancies out of 208.2 million pregnancies globally, there has been an increase in the number of initiatives by governments and NGOs. Furthermore, the report states that one of the major challenges is the introduction of low-cost generic contraceptives. Recently, pharmaceutical companies have introduced new products into their portfolios or diversified their contraceptive drugs and devices. This trend has been primarily supported by several prominent deals or partnerships to develop or introduce new products with better efficacy and safety profiles. These strategic decisions will help companies to generate revenue and acquire a significant share of the Global Contraceptives market. Some of the major acquisitions in this space include Conceptus Inc. by Bayer, Warner Chilcott plc by Actavis, Uteron Pharma SA by Watson Pharmaceuticals Inc., and Barr Pharmaceuticals Inc. by Teva Pharmaceutical Industries. Some of the other prominent deals include Bayer and USAID partnering to make Microgynon, an oral contraceptive and Starpharma Holdings licensing agreement with Okamoto Industries Inc. for the VivaGel-coated condom. The global contraceptives market can be segmented broadly into two divisions: Drugs and Devices. This report covers the present scenario and the growth prospects of the Global Contraceptives market for the period 2013-2018. To calculate the market size, the report considers revenue generated from the sales of various products used for contraception which include: - Drugs (Oral Contraceptive Pills, Injectable Contraceptives, Topical Contraceptives) - Devices (Male & Female condoms, Diaphragms, IUDs, Vaginal Rings, Female Sponges and Subdermal Contraceptive Implants) Key Vendors: - Actavis plc - Bayer AG - Johnson & Johnson's Janssen Pharmaceuticals, Inc. - Merck & Co. - Pfizer, Inc. - Teva Pharmaceutical Industries, Ltd Other Prominent Vendors: - Adamis Pharmaceuticals Corp. - Agile Therapeutics, Inc. - ANI Pharmaceuticals, Inc. - Ansell Ltd. - Apothecus Pharmaceutical Corp. - Blairex Laboratories Inc. - Church & Dwight, Co. Inc. - Caldwell Consumer Health, LLC. - Ferring International Center S.A - Fuji Latex Co., Ltd. - HLL Lifecare Limited - Mayer Laboratories - Medicines 360 - Karex Berhad - Lipocine Inc. - Lupin Pharmaceuticals, Inc. - Mylan Laboratories Inc. - Okamoto Industries, Inc. - Pantarhei Bioscience B.V. - Paul Hartmann AG - Reckitt Benckiser Group Plc - The Female Health Company For more information visit http://www.researchandmarkets.com/research/d964b9/global
Cognitive Impairment Associated With Schizophrenia (CIAS) Clinical Trials Review, H1, 2014
M2 - Tue Jul 08, 10:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/85qd7j/cognitive) has announced the addition of the "Cognitive Impairment Associated With Schizophrenia (CIAS) Global Clinical Trials Review, H1, 2014" report to their offering. Cognitive Impairment Associated With Schizophrenia (CIAS) Global Clinical Trials Review, H1, 2014" provides data on the Cognitive Impairment Associated With Schizophrenia (CIAS) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cognitive Impairment Associated With Schizophrenia (CIAS). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cognitive Impairment Associated With Schizophrenia (CIAS). Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - Pfizer Inc. - Novartis AG - Merck & Co., Inc. - AbbVie Inc. - Takeda Pharmaceutical Company Limited - Saniona AB - Johnson & Johnson - GlaxoSmithKline plc - VA Greater Los Angeles Healthcare Center - Hamamatsu University School of Medicine - Bronx Veterans Medical Research Foundation - Mashhad University of Medical Sciences - St. Marianna University School of Medicine - Yale University - Indiana University - Central South University - University of Southern Denmark - Northwestern University For more information visit http://www.researchandmarkets.com/research/85qd7j/cognitive
United States Hernia Repair Market Outlook to 2020
M2 - Tue Jul 08, 10:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sd7758/united_states) has announced the addition of the "United States Hernia Repair Market Outlook to 2020" report to their offering. "United States Hernia Repair Market Outlook to 2020", provides key market data on the United States Hernia Repair market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments - Synthetic Meshes (Synthetic Flat Meshes and Synthetic 3D Meshes), Composite Meshes and Biological Meshes. The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Hernia Repair market wherever available. The data in the report is derived from dynamic market forecast models. The objective is to provide information that represents the most up-to-date data of the industry possible. Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis. Scope - Market size data for Hernia Repair market segments - Synthetic Meshes (Synthetic Flat Meshes and Synthetic 3D Meshes), Composite Meshes and Biological Meshes. - Annualized market revenues (USD million), volume (units) and average prices (in US dollars) data for each of the market segments. Data is provided from 2005 to 2013 and forecast to 2020. - 2013 company shares and distribution shares data for Hernia Repair market. - Global corporate-level profiles of key companies operating within the Hernia Repair market. Key players covered include: - C. R. Bard, Inc. - Johnson & Johnson - Covidien plc - B. Braun Melsungen AG For more information visit http://www.researchandmarkets.com/research/sd...ted_states
Kony Appoints Two Industry Luminaries to Complete Executive Team
Business Wire - Tue Jul 08, 10:00AM CDT
Kony, Inc., the leading enterprise mobility company, today announced the appointment of Blake P. Salle as president of field operations and Neeraj Nityanand as executive vice president of global services and support. Salle will focus on driving Kony's continued growth and global expansion, while Nityanand will ensure Kony delivers the highest level of value and service to its growing base of Fortune 2000 customers.
